Shanghai, China, 31 August 2022 – Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP” or the “Company”), a global medical device company in the field of electrophysiological interventional diagnosis and ablation therapy, today announced it has successfully listed on the STAR Board of Shanghai Stock Exchange (“SSE STAR Market”). MicroPort EP became the first company listed under the “Guidelines of Shanghai Stock Exchange for the Application of the Rules for Issuance and Listing Review on the STAR Market No. 7 – Medical Device Companies under the Fifth Set of Listing Standards” published and implemented on June 10, 2022.

Since inception in 2010, MicroPort EP has committed to the R&D of innovative medical devices in the field of electrophysiological interventional therapy and ablation therapy and has formed a leading technological advantage. After more than a decade of continuous innovation, the Company has become one of the few players in the global market that provide a complete product layout of cardiac EP devices and consumables. It is also the first domestic entrant in China to provide comprehensive solutions spanning 3D cardiac EP devices and consumables, breaking the long-held technological monopoly by well-known international manufactures.

In the field of electrophysiological intervention, the Columbus™ 3D EP Navigation System independently developed by MicroPort EP as the first domestic electromagnetic and impedance based navigation system approved for marketing in China, marking the first-ever global leadership enjoyed by a Chinese company in the field of high-end cardiac electrophysiology devices.

In terms of ablation therapy, MicroPort EP has achieved major breakthroughs in the two mainstream thermal energy ablation techniques – RF and cryoablation – by relying on its technology platform for thermal energy therapy. While further strengthening the leading position of its established products such as cardiac RF ablation catheters and irrigated ablation catheters, the Company has also submitted registration applications for its high-precision catheters, notably the contact force-sensing RF ablation catheter. In addition, a next-generation cardiac cryoablation project has entered the clinical application stage. In terms of renal artery ablation, the homegrown Flashpoint™ Renal Artery RF Ablation Catheter was admitted to the Special Approval Procedure for Innovative Medical Devices in 2017.

Thanks to the rich understanding and experience gained by the Company over the years, MicroPort EP products are now available in more than 700 local hospitals in 31 provinces, autonomous regions, and municipalities in China. Its flagship products have been registered in many countries and regions including the EU, Korea, Brazil, Argentina, Russia, India, and Australia, and are being exported to 22 countries and regions including France, Italy, and Spain. So far, the Company has obtained 24 medical device registration certificates and filing issued by NMPA, 4 CE registration certifications, and many more registration certificates issued by overseas authorities.

At the same time, MicroPort EP is also actively seeking strategic partnerships around the world. In August 2021, the Company jointly announced the cooperation with Stereotaxis (NYSE:STXS) to become the exclusive distributor for the magnetic navigation EP robotic devices of Stereotaxis in mainland China. Through the strategic partnership, the two parties will combine MicroPort EP’s rich commercial and product experience in the domestic market and Stereotaxis’ advanced magnetic navigation EP robotics, to boost the technological innovation and commercial application of EP robotics in China. In the future, MicroPort EP will further enrich its technology reserve in the field of EP intervention and ablation therapy and continue to augment its R&D effort in the areas of image navigation technology, ablation energy technology, and precision sensing technology by leveraging emerging technologies such as big data and artificial intelligence. In doing so, the Company is expected to continuously enhance its technical advantages, further expand the applicability of its key products, and build a broader product portfolio to provide more patients around the world with integrated solutions of diagnosis and ablation therapy centering on precision interventional navigation.

Dr Yiyong Sun, President of MicroPort EP, stated: “The field of electrophysiology features high technical standards and cross-disciplinary collaboration and relies heavily on the advancement of biomedical technology, materials technology, electronic information engineering, and other technologies. As a company that has always placed great importance on the deep integration of scientific and technological achievements into industrial applications, MicroPort EP will continue to dive deep into this field for technological breakthroughs, improve its product performance, and actively promote the broader availability and application of its products. MicroPort EP will also actively implement China's hierarchical diagnosis and treatment system, and continue to help primary hospitals improve their EP diagnosis and treatment quality as a way to support the development EP industry in China.”

“The listing of MicroPort EP on the STAR Market makes it the first medical device company to have been approved under the fifth set of STAR Market listing guidelines. It provides a better platform for our future development and allows us to better contribute to the development of the medical device industry around the world,” commented Dr Qiyi Luo, Chief Technology Officer of MicroPort^® and Chairman of MicroPort EP, “With the support of the capital market, we will be able to further promote innovation and develop world-leading products with excellent quality,” he added.

Mr Zheyi Gu, Chairman of MicroPort EP, commented: “We should not only strive to develop the domestic market, but also embrace a global vision and aspire to serve the broader global market well. MicroPort EP has always been an industry leader in China in terms of going global. In the future, we will further accelerate our strategic development of internationalization, strengthen the global sales network, continuously improve our brand awareness globally, and strive to become an international medical device company serving the world as it takes root in China.”